Zenlabs Ethica Ltd Share Price Today - Zenlabs Ethica Ltd Stock Price Live NSE/BSE

Zenlabs Ethica Ltd

NSE: BSE: 530697

₹19.65

(-3.53)%

Fri, 13 Feb 2026, 06:23 am

MTF 5xInvest in Zenlabs Ethica Ltd with 5x Leverage Buy with MTF

Market Cap-

PE Ratio-

Dividend-

Health Technology

Pharmaceuticals: Generic

24.5K

1 Day

0 (0%)

No Result Found

Summary

Market Cap
12.79
Net Profit
0.27
P/B
1.95
Sector P/E
40.30
P/E
76.12
EV/EBITDA
11.92
Debt/Equity (Industry)
0.46
Interest Cover (Industry)
2.28
ROCE (Industry)
3.64
RONW (Industry)
1.83
ROE
2.63
ROCE
5.32
Debt/Equity
1.34
EPS (TTM)
0.36
Dividend Yield
0
Book Value
16.21
Interest Cover
1.46

Analysis

all

Pros

Zenlabs Ethica is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Zenlabs Ethica has been profitable on average in the past, therefore cash runway is not a concern.
Zenlabs Ethica has been profitable on average in the past, therefore cash runway is not a concern.
Debt is well covered by operating cash flow (163.1%, greater than 20% of total debt).
Debt is covered by short term assets, assets are 65x debt.

Cons

Unable to evaluate Zenlabs Ethica's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Zenlabs Ethica's dividend against the top 25% market benchmark as the company has not reported any payouts.
Sanjeev's remuneration is higher than average for companies of similar size in India.
Zenlabs Ethica is not covered by any analysts.
Zenlabs Ethica has significant price volatility in the past 3 months.

Financials

No Result Found

Ratios

No Result Found

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	52.96	52.96	52.96	52.96	52.96
FII	0	0	0	0	0
DII	0	0	0	0	0
Public	47.04	47.04	47.04	47.04	47.04
Government	0	0	0	0	0

Technical Analysis

RSI

47.13

MACD

-0.38

50 DMA

20.72

200 DMA

29.19

Support and Resistance

Type	R1	R2	R3	PP	S1	S2	S3
Classic	31.42	25.90	22.76	20.38	17.24	14.86	9.34
Fibonacci	25.90	23.79	22.49	20.38	18.27	16.97	14.86
Camarilla	21.13	20.62	20.12	20.38	19.10	18.60	18.09

Pivots Level: Classic

+11.04

31.42

+5.52

25.90

+2.37

22.76

20.38

Pivot Point

LTP: 19.65

-3.15

17.24

-5.52

14.86

-11.04

9.34

Moving Average

SMAEMA

Period

Value

10-EMA
19.60
20-EMA
19.73
30-EMA
20.19
50-EMA
21.48
100-EMA
24.37
200-EMA
27.99

Announcement Date	Purpose	Action	Ex Date
07 Feb 2026	board-meetings	Quarterly Results
08 Nov 2025	board-meetings	Quarterly Results
10 Sept 2025	agm
07 Sept 2024	agm
04 Sept 2023	agm
07 Sept 2022	agm
20 Jul 2022	dividend	₹0.25 Dividend /Share	01 Aug 2022
04 Sept 2021	agm
10 Nov 2020	agm

Peer Comparison

No Result Found

Zenlabs Ethica Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Cipla Ltd

Divis Laboratories Ltd

Sun Pharmaceutical Industries Ltd

About Zenlabs Ethica Ltd

Zenlabs Ethica The Company deals in marketing and distribution of pharmaceutical products.

Industry

Trading

Founded

1993

Headquarters

CEO

Employees

Contact

Website

http://www.zenlabsethica.com

preetremedies@gmail.com ; queries@zenlabsethica.co

Phone

91-172-4651105/3920738

Location

Plot No 194-195 3rd Flr Pha-II, Industrial Area Ram Darbar, Chandigarh, Chandigarh, 160002

Year	History
1993	The company was incorporated in the state of Chandigarh, India.
2008	The company name was changed from Shri Lakhavi Infotech Ltd to Neelkanth Technologies Ltd.
2009	Neelkanth Technologies Ltd appointed Mr. Sanjeev Kumar as Managing Director of the Company effective September 01, 2009.
2011	The Registered Office of the Company was shifted to Plot No. 194-195, 3rd Floor, Industrial Area, Phase II, Ram Darbar, Chandigarh - 160 002.
2018	The Company issued Bonus Shares in the Ratio of 1:20.

Client Name	Order Side	QTY	Avg Price	Date
No Result Found

zenlabs ethica limited News

Zenlabs Ethica Q3FY26 Loss Widens on NBFC Exit

Zenlabs Ethica reported a net loss of ₹200.76 lakhs in Q3FY26 due to ₹207.81 lakhs exceptional item from NBFC business exit following RBI registration cancellation in November 2025.

07 Feb 2026

co actions results

Zenlabs Ethica Limited Company Secretary Resigns for Better Opportunity

Ms. Manju Bala resigned from her position as Company Secretary and Compliance Officer at Zenlabs Ethica Limited due to a better opportunity with another organization. Her resignation became effective from the close of business hours on December 04, 2025, after serving a 15-day notice period from November 20, 2025.

04 Dec 2025

corporate governance

Zenlabs Ethica Reports Quarterly Financial Results for Quarter Ended September 30, 2025

Zenlabs Ethica Limited announced its unaudited financial results for the quarter and half year ended September 30, 2025. The Board of Directors approved the results at a meeting held on November 8, 2025. The company operates as a single segment business engaged in trading of pharmaceutical formulations. The results were reviewed by the Audit Committee and statutory auditors N Kumar Chhabra and Co. expressed an unmodified opinion on the financial results. The financial statements were prepared in accordance with Indian Accounting Standards (IndAS) and comply with the Companies Act, 2013 provisions.

08 Nov 2025

earnings

Zenlabs Ethica Reports Strong Q1 FY2026 Results with 21.9% Revenue Growth

Zenlabs Ethica Limited reported Q1 FY2026 revenue of ₹957.50 crore, up 21.9% year-on-year from ₹785.00 crore. EBITDA grew 29.4% to ₹212.98 crore with margin expansion of 130 basis points to 22.2%. Profit after tax increased 50.9% to ₹131.90 crore compared to ₹87.40 crore in the previous year. The company launched 3 new products in domestic formulations, filed 2 new ANDAs with USFDA, and received approval for 1 generic product. The new oral solid dosage facility in Baddi commenced commercial production with capacity utilization of 78% across manufacturing facilities. The company maintains net cash of ₹205.98 crore and published results in Financial Express and Dainik Tribune newspapers with QR code access to complete financial results.

09 Aug 2025

earnings

Zenlabs Ethica Reports Net Profit of ₹3.33 Crore for June Quarter, Adopts New Insider Trading Policies

Zenlabs Ethica Limited reported a net profit of ₹3.33 crore for the quarter ended June 30, 2025, compared to ₹4.18 crore in the same period last year. Revenue from operations declined to ₹1,147.72 crore from ₹1,236.26 crore year-on-year. The pharmaceutical trading company's total income decreased to ₹1,148.15 crore from ₹1,236.54 crore. Basic and diluted earnings per share stood at ₹0.05 compared to ₹0.06 in the previous year. The company's Board also approved new insider trading policies including codes for fair disclosure of unpublished price sensitive information and internal procedures for regulating trading by insiders. The policies establish trading window closures, structured digital databases for information sharing, and compliance frameworks. The company operates as a single segment entity engaged in pharmaceutical formulation trading with paid-up equity share capital of ₹651 crore.

08 Aug 2025

earnings

Showing 1–5 of 5

Rows per page:

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800